A Look at Lupus
Human Genome's Benlysta: First of Many or a Fluke?
By Brian Orelli
Monday, March 14, 2011
After a 56-year dearth, the FDA has finally signed off on a new medication for lupus. Last week, the agency approved Human Genome Sciences Inc.'s and partner GlaxoSmithKline plc's Benlysta (belimumab) for treating systemic lupus erythematosus (SLE). (See Bioworld Today, Mar. 11, 2011.)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.